Pliant Therapeutics Q1 net loss $20M; doses first patient in Phase 1b FORTIFY trial

PLIANT THERAPEUTICS, INC.

• Q1 net loss $20.0M vs $56.2M prior year; R&D expense $13.6M (down from $43.4M) due to bexotegrast termination and reduced headcount.
• Cash, equivalents and short-term investments $172.4M; expected to fund operations into H2 2028.
• First patient dosed in FORTIFY Phase 1b trial of PLN-101095; interim data expected in 2027.
• Updated Phase 1 data at AACR showed deepening responses: one complete response, two partial responses in checkpoint-refractory tumors.
• Integrin-targeted delivery platform advancing for siRNA delivery to skeletal muscle; preclinical proof-of-concept ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.